Tags

Type your tag names separated by a space and hit enter

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
Value Health. 2004 Jan-Feb; 7(1):36-51.VH

Abstract

BACKGROUND

Streptococcus pneumoniae is a leading cause of illness in children. Seven-valent pneumococcal conjugate vaccine (PCV-7), recently approved in the United States, is the first vaccine to provide protective immunity against pneumococcal disease in children under the age of 2. PCV-7 is nearly 100% effective in preventing invasive pneumococcal infections and has been shown to significantly decrease the incidence of pneumonia and otitis media.

OBJECTIVE

The objective of this study was to evaluate the health outcomes, costs, and cost-effectiveness of vaccination with PCV-7, compared with no vaccination for children in Spain.

METHODS

A health state model was used to determine the health and economic outcomes in vaccinated and unvaccinated groups among children less than 5 years old. This analysis was conducted for a 10-year time horizon, beginning with initial vaccinations. Information on the burden of pneumococcal disease, in terms of data on the incidence and seroprevalence of disease, was collected from published and unpublished records, supplemented, and verified by Spanish pediatric and infectious disease experts. The efficacy of PCV-7 was based on updated findings of the Kaiser Permanente Efficacy Study. A cost-of-illness estimate for each pneumococcal disease was determined using decision tree analysis that considered direct and indirect costs. A birth cohort analysis compared the expected cost of vaccinated populations to age-matched unvaccinated populations.

RESULTS

Implementing a PCV-7 vaccine program in Spain in a birth cohort of 360000 is expected to save approximately 16 lives and 132000 cases of pneumococcal disease over 10 years, resulting in total savings estimated at Euros 81 million (ESP13.5 billion), of which Euros 43.5 million (ESP7.1 billion) are direct medical savings. At a vaccine cost up to Euros 56.87 per dose (ESP9,462, the total cost of vaccinating a birth cohort of 360000 will be offset by the total savings owing to reduced morbidity.

CONCLUSIONS

Implementing a universal PCV-7 vaccination program in Spain will significantly decrease the mortality and morbidity associated with pneumococcal infections in young children. At an assumed cost of Euros 48.56 (ESP8080) per dose, PCV-7 vaccination of Spanish children under the age of 5, followed over a 10-year period, is cost saving from the societal perspective and cost-effective from the payer perspective at Euros 22500 per LYG (ESP3,734713), comparing favorably with other preventive programs in Spain.

Authors+Show Affiliations

Hospital Universitario La Fe, Valencia, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14720129

Citation

Asensi, Francisco, et al. "A Pharmacoeconomic Evaluation of Seven-valent Pneumococcal Conjugate Vaccine in Spain." Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 7, no. 1, 2004, pp. 36-51.
Asensi F, De Jose M, Lorente M, et al. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health. 2004;7(1):36-51.
Asensi, F., De Jose, M., Lorente, M., Moraga, F., Ciuryla, V., Arikian, S., Casciano, R., & Vento, M. (2004). A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research, 7(1), 36-51.
Asensi F, et al. A Pharmacoeconomic Evaluation of Seven-valent Pneumococcal Conjugate Vaccine in Spain. Value Health. 2004 Jan-Feb;7(1):36-51. PubMed PMID: 14720129.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. AU - Asensi,Francisco, AU - De Jose,Maribel, AU - Lorente,Manuel, AU - Moraga,Fernando, AU - Ciuryla,Vincent, AU - Arikian,Steve, AU - Casciano,Roman, AU - Vento,Maximo, PY - 2004/1/15/pubmed PY - 2004/3/12/medline PY - 2004/1/15/entrez SP - 36 EP - 51 JF - Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research JO - Value Health VL - 7 IS - 1 N2 - BACKGROUND: Streptococcus pneumoniae is a leading cause of illness in children. Seven-valent pneumococcal conjugate vaccine (PCV-7), recently approved in the United States, is the first vaccine to provide protective immunity against pneumococcal disease in children under the age of 2. PCV-7 is nearly 100% effective in preventing invasive pneumococcal infections and has been shown to significantly decrease the incidence of pneumonia and otitis media. OBJECTIVE: The objective of this study was to evaluate the health outcomes, costs, and cost-effectiveness of vaccination with PCV-7, compared with no vaccination for children in Spain. METHODS: A health state model was used to determine the health and economic outcomes in vaccinated and unvaccinated groups among children less than 5 years old. This analysis was conducted for a 10-year time horizon, beginning with initial vaccinations. Information on the burden of pneumococcal disease, in terms of data on the incidence and seroprevalence of disease, was collected from published and unpublished records, supplemented, and verified by Spanish pediatric and infectious disease experts. The efficacy of PCV-7 was based on updated findings of the Kaiser Permanente Efficacy Study. A cost-of-illness estimate for each pneumococcal disease was determined using decision tree analysis that considered direct and indirect costs. A birth cohort analysis compared the expected cost of vaccinated populations to age-matched unvaccinated populations. RESULTS: Implementing a PCV-7 vaccine program in Spain in a birth cohort of 360000 is expected to save approximately 16 lives and 132000 cases of pneumococcal disease over 10 years, resulting in total savings estimated at Euros 81 million (ESP13.5 billion), of which Euros 43.5 million (ESP7.1 billion) are direct medical savings. At a vaccine cost up to Euros 56.87 per dose (ESP9,462, the total cost of vaccinating a birth cohort of 360000 will be offset by the total savings owing to reduced morbidity. CONCLUSIONS: Implementing a universal PCV-7 vaccination program in Spain will significantly decrease the mortality and morbidity associated with pneumococcal infections in young children. At an assumed cost of Euros 48.56 (ESP8080) per dose, PCV-7 vaccination of Spanish children under the age of 5, followed over a 10-year period, is cost saving from the societal perspective and cost-effective from the payer perspective at Euros 22500 per LYG (ESP3,734713), comparing favorably with other preventive programs in Spain. SN - 1098-3015 UR - https://www.unboundmedicine.com/medline/citation/14720129/A_pharmacoeconomic_evaluation_of_seven_valent_pneumococcal_conjugate_vaccine_in_Spain_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1098-3015(10)60179-9 DB - PRIME DP - Unbound Medicine ER -